Galectin Therapeutics (GALT) Equity Average (2011 - 2026)
Galectin Therapeutics' quarterly Equity Average came in at -$129.9 million in Q1 2026, down 18.79% year-on-year from -$160.0 million in Q1 2025, and down 2.63% quarter-over-quarter from -$126.6 million in Q4 2025.
Galectin Therapeutics has reported Equity Average for 16 years, with the latest figure at -$129.9 million in Q1 2026.
- For the quarter ending Q1 2026, Equity Average fell 18.79% year-over-year to -$129.9 million; the trailing twelve-month figure through Mar 2026 stood at -$129.9 million (down 18.79% YoY), and the FY2025 full-year result was -$116.4 million, down 39.55% from the prior year.
- Equity Average for Q1 2026 stood at -$129.9 million, down from -$126.6 million in the prior quarter.
- The five-year high for Equity Average was -$3.5 million in Q1 2022, with the low at -$129.9 million in Q1 2026.
- Average Equity Average over 5 years is -$69.0 million, with a median of -$57.3 million recorded in 2023.
- Year-over-year, Equity Average sank 1014.71% in 2023 and decreased 18.79% in 2026.
- Tracing GALT's Equity Average over 5 years: stood at -$29.0 million in 2022, then tumbled by 97.6% to -$57.3 million in 2023, then tumbled by 73.71% to -$99.5 million in 2024, then fell by 27.25% to -$126.6 million in 2025, then retreated by 2.63% to -$129.9 million in 2026.
- The last three Equity Average figures came in at -$129.9 million (Q1 2026), -$126.6 million (Q4 2025), and -$122.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | -129.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -129.94 Mn |
| Dec 31, 2025 | -126.61 Mn |
| Sep 30, 2025 | -122.10 Mn |
| Jun 30, 2025 | -116.44 Mn |
| Mar 31, 2025 | -109.39 Mn |
| Dec 31, 2024 | -99.50 Mn |
| Sep 30, 2024 | -89.04 Mn |
| Jun 30, 2024 | -64.12 Mn |
| Mar 31, 2024 | -53.17 Mn |
| Dec 31, 2023 | -57.28 Mn |
| Sep 30, 2023 | -52.72 Mn |
| Jun 30, 2023 | -48.61 Mn |
| Mar 31, 2023 | -39.14 Mn |
| Dec 31, 2022 | -28.99 Mn |
| Sep 30, 2022 | -20.50 Mn |
| Jun 30, 2022 | -12.43 Mn |
| Mar 31, 2022 | -3.51 Mn |
| Dec 31, 2021 | 4.21 Mn |
| Sep 30, 2021 | 11.46 Mn |
| Jun 30, 2021 | 15.95 Mn |
| Mar 31, 2021 | 19.49 Mn |
| Dec 31, 2020 | 26.14 Mn |
| Sep 30, 2020 | 32.55 Mn |
| Jun 30, 2020 | 38.16 Mn |
| Mar 31, 2020 | 42.45 Mn |
| Dec 31, 2019 | 45.82 Mn |
| Sep 30, 2019 | 48.83 Mn |
| Jun 30, 2019 | 27.51 Mn |
| Mar 31, 2019 | 5.15 Mn |
| Dec 31, 2018 | 6.21 Mn |
| Sep 30, 2018 | 7.65 Mn |
| Jun 30, 2018 | 4.49 Mn |
| Mar 31, 2018 | 197,500.00 |
| Dec 31, 2017 | 208,500.00 |
| Sep 30, 2017 | 2.52 Mn |
| Jun 30, 2017 | 6.00 Mn |
| Mar 31, 2017 | 9.10 Mn |
| Dec 31, 2016 | 10.30 Mn |
| Sep 30, 2016 | 8.90 Mn |
| Jun 30, 2016 | 9.98 Mn |
| Mar 31, 2016 | 15.26 Mn |
| Dec 31, 2015 | 15.44 Mn |
| Sep 30, 2015 | 15.36 Mn |
| Jun 30, 2015 | 19.86 Mn |
| Mar 31, 2015 | 21.52 Mn |
| Dec 31, 2014 | 22.21 Mn |
| Sep 30, 2014 | 24.47 Mn |
| Jun 30, 2014 | 27.00 Mn |
| Mar 31, 2014 | 14.87 Mn |
| Dec 31, 2013 | 1.39 Mn |
| Sep 30, 2013 | -894,500.00 |
| Jun 30, 2013 | -2.06 Mn |
| Mar 31, 2013 | 64,500.00 |
| Dec 31, 2012 | 2.11 Mn |
| Sep 30, 2012 | 3.98 Mn |
| Jun 30, 2012 | 5.87 Mn |
| Mar 31, 2012 | 2.35 Mn |
| Dec 31, 2011 | -651,000.00 |
| Sep 30, 2011 | 869,000.00 |